北京若生智能科技有限公司
Drug Database
MO

mometasone furoate (Monovo / H527722 / Mundoson)

✓ Approved

Almirall, S.A · NR3C1 · 小分子

什么是 mometasone furoate？

mometasone furoate 是一种小分子，由Almirall, S.A研发。该药已获批，用于治疗相关适应症，给药途径：Topical。

药物档案

商品名Monovo, H527722, Mundoson
公司Almirall, S.A
药物类别小分子
分子靶点NR3C1, NR3C2
给药途径Topical
状态Approved
来源： ClinicalTrials.gov, Almirall, S.A

作用机制

分子靶点

mometasone furoate 作用于 2 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

mometasone furoate 针对 3 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

相关研究文献

PubMedJMIR formative research2026-09-07

Effectiveness of the Prospective Prescription Review System in Reducing Irrational Prescriptions at a Tertiary Specialty Hospital: Retrospective Cohort Study.

Tang Fengmin F, Zhang Min M, Shen Jianwen J, Yan Jingchao J et al.

The prospective prescription review system can improve prescription rationality, but its effectiveness in high-volume specialty care settings is not well established. We aimed to evaluate the effectiveness of the prospective prescription review system in reducing irrational prescriptions and to analyze factors associated with successful interception. This retrospective cohort study analyzed all outpatient and emergency prescriptions issued between January 1 and December 31, 2024, at an eye, ear, nose, and throat tertiary hospital in Shanghai, China. Among 2,559,342 prescriptions, 123,914 (4.84%) flagged as irrational by the prospective prescription review system were included. The overall interception success rate was 32.99% (40,877/123,914). The prescription rationality rate increased from 95.23% (2,476,305/2,600,219) to 96.79% (2,477,144/2,559,342) after excluding intercepted prescriptions (P<.001). Higher review levels were strongly associated with higher interception success rates: 0.99% (517/52,146) for reminder, 54.2% (37,039/68,341) for warning, and 96.91% (3321/3427) for mandatory (P<.001). Revised prescriptions had a higher interception success rate than prescriptions without revision (35,008/50,418, 69.44% vs 5869/73,496, 7.99%; P<.001). Prescriptions without documented reasons showed a higher interception success rate than those with documented reasons (40,086/98,070, 40.87% vs 791/25,844, 3.06%; P<.001). Physician acceptance of pharmacist disapproval was associated with a successful interception rate of 85.63% (137/160), compared with 3.33% (2/60) when the disapproval was rejected (P<.001). Multivariable logistic regression showed that inappropriate dosage or frequency (odds ratio [OR] 3.11, 95% CI 2.99-3.24) and inappropriate prescription quantity (OR 2.09, 95% CI 2-2.18) were most likely to be intercepted, whereas inappropriate indications (OR 0.04, 95% CI 0.03-0.04) and radiation oncology (OR 0.01, 95% CI 0.01-0.02; P<.001) were more likely to be issued. Pharmacist-led rule revision for mometasone furoate nasal spray led to a 1000-fold increase in identified irrational prescriptions (from 2-4 per month to 3022 in May). The interrupted time series analysis showed that the April revision was associated with an immediate and statistically significant increase in the monthly overall interception success rate (intervention coefficient = 0.15; P =.005). The prospective prescription review system substantially reduced irrational prescriptions and improved prescription rationality. Higher review levels were associated with higher interception rates, and physicians' attitudes also played a critical role. Paired-organ dose standardization emerged as an important consideration in ophthalmology and otolaryngology practice. Collaboration between the prospective prescription review system and pharmacists is essential for optimizing prescription review outcomes.

PMID 42704205
阅读全文 →
PubMedReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026-09-06

A systematic review: management of radiation-induced moist desquamation.

Raja Sneha S, Kuppusamy Sujatha S, Johnson Christian Gnanaraj CG, Jayram Jayasutha J et al.

Radiotherapy is a cornerstone in cancer treatment, but is frequently correlated with acute cutaneous toxicity, particularly in patients with head, neck, and breast cancers. This systematic review evaluates the efficacy of interventions for managing grade III moist desquamation among various cancer patients receiving radiotherapy. A total of 676 studies were screened, and 10 randomised controlled trials were analysed based on inclusion criteria. Interventions such as Mepitel Film, boron-based gel, and 0.1% Mometasone Furoate demonstrated significant efficacy in reducing the incidence and severity of moist desquamation compared to standard creams or placebo. Hydroactive colloid gels and aloe vera showed promise in alleviating symptoms and improving treatment adherence. Betamethasone effectively reduced grade 2 dermatitis but limitedly impacted severe grade 3 reactions. The findings highlight the importance of tailoring interventions to individual patient needs and emphasize the need for further studies to validate treatments, explore long-term outcomes, and improve patient quality of life during radiotherapy.

PMID 42699636
阅读全文 →
PubMedInternational journal of clinical pharmacology and therapeutics2026-09-03

Sleep apnea-hypopnea in children: Evidence that Lize Tongqi decoction with acupuncture, moxibustion, and Xinwu acupoint stimulation is superior to standard Western treatment using montelucast/mometasone furoate.

Wang Yu-Jie YJ, Li Miao-Yuan MY, Zheng Yong Y, Wang Bei B et al.

To assess the clinical efficacy of a modified Lize Tongqi decoction in combination with acupuncture, moxibustion, and local stimulation of the Xinwu acupoint in the treatment of pediatric snoring. A randomized controlled trial was conducted in a cohort of 60 pediatric patients (mean age of 7.9 years) diagnosed with snoring. Patients were assigned to either a study group (n = 30) or a control group (n = 30). The study group was treated using modified Lize Tongqi decoction, acupuncture, moxibustion, and stimulation of the Xinwu acupoint (twice weekly for 8 weeks) whereas the control group was treated with conventional Western medicine (oral montelukast once nightly and mometasone furoate nasal spray once nightly for 8 weeks). The severity of symptoms including nasal congestion, nocturnal snoring, and breathing through the mouth was assessed prior to, and following the treatment intervention. Changes in the Obstructive Sleep Apnea-18 (OSA-18) quality of life score and the adenoid-to-nasopharyngeal (A/N) ratio were measured and compared between groups. Post-treatment comparisons showed significantly greater improvements in nasal congestion, snoring, and breathing through the mouth in the study group, and the reductions in both OSA-18 scores and A/N ratios were significantly greater. (Between-group differences p < 0.05). No adverse events were observed in either group. The combination of modified Lize Tongqi decoction with acupuncture, moxibustion, and Xinwu acupoint stimulation effectively reduced symptoms of airway obstruction and improved quality of life in pediatric patients with snoring. The combination therapy is a new, non-surgical therapeutic option for the clinical management of this potentially serious disorder.

PMID 42687844
阅读全文 →
PubMedCHEST pulmonary2026-09-03

Medium-Dose Compared With High-Dose Inhaled Corticosteroids in Combination Triple Inhaler Therapy for Asthma: A Systematic Review and Meta-Analysis.

Warhurst Samantha S, Cullen Ryan R, Sayers Ross R, Lynch Francesca F et al.

Combination inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) triple therapy is used in severe asthma. The clinical effect of high-dose (HD) vs medium-dose (MD) ICSs in ICS/LABA/LAMA is unclear. What is the clinical effect of HD compared with MD ICSs in ICS/LABA/LAMA treatment of asthma? A systematic review and meta-analysis of randomized controlled trials including > 1 ICS dose in ICS/LABA/LAMA inhalers compared the outcomes of HD and MD ICS/LABA/LAMA. The primary outcome was the proportion of participants with ≥ 1 severe asthma exacerbations. Secondary outcomes included FEV1, the Asthma Control Questionnaire, emergency department visits, and hospital admissions. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations domains. Three randomized controlled trials (N = 3,804) were identified, comparing MD and HD ICS/LABA/LAMA containing fluticasone or mometasone. When comparing HD with MD ICS/LABA/LAMA for at least 1 severe exacerbation, the Peto OR was 0.81 (95% CI, 0.68-0.96; P = .01). This corresponds to a number needed to treat to prevent 1 severe exacerbation of 32.9. HD ICS/LABA/LAMA led to a higher FEV1 (mean difference, 50.8 mL; 95% CI, 29.5-72.2 mL; P < .001) and a lower (improvement) Asthma Control Questionnaire (mean difference, -0.09; 95% CI, -0.15 to -0.04; P < .001) than MD ICS/LABA/LAMA. There was no statistically significant difference in emergency department visits (Peto OR, 0.51; 95% CI, 0.25-1.04; P = .07) or hospitalizations (Peto OR, 0.65; 95% CI, 0.33-1.29; P = .22) between HD and MD ICS/LABA/LAMA. Our results show that HD compared with MD ICS/LABA/LAMA reduces the odds of a severe exacerbation by about 20%. This absolute risk reduction was modest but may be clinically relevant for patients with high baseline exacerbation rates and those with high type 2 inflammation. At both the individual and population level, the use of HD ICS/LABA/LAMA needs to be considered alongside the potential systemic side effects. PROSPERO Registry; No.: CRD42025634340; URL: https://www.crd.york.ac.uk/prospero/.

PMID 42688694
阅读全文 →
PubMedJournal of pharmaceutical sciences2026-08-29

A combined approach for full API particle size distribution characterization in nasal spray suspensions based on their dissolution behavior.

Cheng Yushan Y, Shu Hong H, Zhang Yingjun Y, Qin Lina L et al.

Determining the particle size distribution (PSD) of the active pharmaceutical ingredient (API) in nasal spray suspensions is a challenging task that usually requires the use of morphologically-directed Raman spectroscopy (MDRS). A dissolution-based modeling strategy was established to characterize the entire PSD of starting API in mometasone furoate nasal sprays using dissolution data of finished formulations, whereas MDRS measures API PSD in the final products. A dissolution-PSD model was built in-house to derive the API PSD from the dissolution data of target products, with model parameters estimated using test products with known raw API PSD and dissolution profiles. To obtain representative dissolution data that could better reflect the intrinsic API PSD characteristics of the formulation, different sample pretreatment procedures and dissolution approaches were investigated. The results suggested that the dissolution profile acquired by the paddle method following combined enzymatic hydrolysis and ultrasonication pretreatment was preferable for characterizing the starting API particle size features. Model predictions demonstrated that the commercial Nasonex® displayed a bimodal volume-weighted PSD and a relatively high Dv90 of 15.8 μm, which differed from previous reports. A modified MDRS was applied for cross-checking, and the modeled Dv90 was in agreement with the measured results. Cross-validation for the model using five test batches yielded prediction errors mostly <10%, indicating acceptable performance. For nasal suspension products that typically present complex PSD features, the present method may provide a feasible auxiliary tool for guiding formulation screening and optimizing manufacturing parameters in the preliminary development stage.

PMID 42667955
阅读全文 →
PubMedBiomedicines2026-08-27

COPD Stability and Asthma Remission: Different Words for the Same Therapeutic Ambition?

Carriera Lorenzo L, Mari Pier-Valerio PV, Lipsi Roberto R, Ielo Simone S et al.

The therapeutic goals related to chronic airway diseases are evolving from short-term symptom control toward sustained suppression of disease activity and prevention of future risk. In severe asthma, this shift has been captured by the concept of clinical remission, generally defined by absence of exacerbations, no need for oral corticosteroids, symptom control, and stable or improved lung function. In chronic obstructive pulmonary disease (COPD), the analogous concept has more often been described as disease stability. Although remission in asthma and stability in COPD have developed within different biological and clinical frameworks, they may reflect disease-specific expressions of the same therapeutic ambition. Recent studies support COPD stability as a measurable and clinically meaningful state, associated with reduced exacerbation risk and mortality. Evidence from optimized inhaled triple therapy, particularly with fluticasone furoate/umeclidinium/vilanterol, indicates that multidimensional stability can be achieved and maintained in a proportion of patients, while real-world studies reinforce its applicability beyond randomized trials. The emergence of biologic therapies for selected patients with eosinophilic or type 2 COPD further strengthens the rationale for considering stability as an ambitious treatment target. In this narrative review, informed by a structured literature search, we discuss the conceptual relationship between asthma remission and COPD stability, and summarize the evidence supporting disease stability as an attainable and prognostically relevant outcome. In addition, we propose a pragmatic multidimensional definition based on symptom stability, absence of moderate or severe exacerbations, no systemic corticosteroid use, and maintained lung function over 12 months. COPD stability should not be viewed as a weaker goal than asthma remission, but rather as the most appropriate COPD-specific expression of sustained low disease activity.

PMID 42652058
阅读全文 →

注册免费账户还可查看另外 2131 篇文献

免费注册查看全部文献 →

了解更多mometasone furoate